RxDoctor Payments Data

Jonah All

Psychiatric/Mental Health · Hendersonville, NCNPI 1669057345

Payments from drug & device makers

$1,359in general payments, 2019–2025

Across 76 payments — averaging $17.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$391
  • Neurocrine Biosciences, Inc.$364
  • Teva Pharmaceuticals USA, Inc.$191
  • Lundbeck LLC$165
  • Takeda Pharmaceuticals U.S.A., Inc.$120
  • Otsuka America Pharmaceutical, Inc.$75
  • plus $54 from 3 others

What the payments were for

  • Food & beverage$1,359100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,359 in reported general payments places this provider in the 70th percentile of 947 psychiatric/mental health providers in North Carolina.

See all psychiatric/mental health providers in North Carolina

Medicare billing

Part B allowed, 2024
$40,373
Medicare patients
119
Services billed
521

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine14$103,545
VraylarCariprazine Hcl59$84,367
Austedo XrDeutetrabenazine11$78,171
RexultiBrexpiprazole25$34,711
Lurasidone Hcl22$24,469
TrintellixVortioxetine Hydrobromide33$23,313
Aripiprazole211$10,438
VyvanseLisdexamfetamine Dimesylate19$7,219
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine218$6,261
Asenapine Maleate12$4,627
Lisdexamfetamine Dimesylate29$4,586
Bupropion XlBupropion Hcl167$3,418
Dextroamphetamine Sulfate ErDextroamphetamine Sulfate11$3,117
Quetiapine Fumarate174$2,864
Clozapine64$2,440

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$191$181,71625 claims
AbbVieVraylar$391$84,36759 claims
Otsuka America Pharmaceutical, Inc.Rexulti$75$34,71125 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$120$30,53252 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 947 psychiatric/mental health providers in North Carolina.

Other psychiatric/mental health in Hendersonville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →